Inovio Pharmaceuticals Inc. (NASDAQ:INO) went down by -5.50% from its latest closing price compared to the recent 1-year high of $33.79. The company’s stock price has collected -9.70% of loss in the last five trading sessions. Press Release reported on 04/09/21 that INOVIO INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inovio Pharmaceuticals Inc. – INO
Is It Worth Investing in Inovio Pharmaceuticals Inc. (NASDAQ :INO) Right Now?
Plus, the 36-month beta value for INO is at 0.76. Opinions of the stock are interesting as 3 analysts out of 9 who provided ratings for Inovio Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 6 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $15.63. INO currently public float of 204.20M and currently shorts hold a 28.00% ratio of that float. Today, the average trading volume of INO was 14.40M shares.
INO’s Market Performance
INO stocks went down by -9.70% for the week, with a monthly drop of -22.04% and a quarterly performance of -10.63%, while its annual performance rate touched 1.48%. The volatility ratio for the week stands at 4.46% while the volatility levels for the past 30 days are set at 5.48% for Inovio Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -13.22% for INO stocks with a simple moving average of -38.70% for the last 200 days.
Analysts’ Opinion of INO
Many brokerage firms have already submitted their reports for INO stocks, with BofA Securities repeating the rating for INO by listing it as a “Neutral.” The predicted price for INO in the upcoming period, according to BofA Securities is $13 based on the research report published on March 23rd of the current year 2021.
Oppenheimer, on the other hand, stated in their research note that they expect to see INO reach a price target of $35. The rating they have provided for INO stocks is “Outperform” according to the report published on February 12th, 2021.
INO Trading at -26.21% from the 50-Day Moving Average
After a stumble in the market that brought INO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.61% of loss for the given period.
Volatility was left at 5.48%, however, over the last 30 days, the volatility rate increased by 4.46%, as shares sank -21.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.75% lower at present.
During the last 5 trading sessions, INO fell by -9.70%, which changed the moving average for the period of 200-days by -65.48% in comparison to the 20-day moving average, which settled at $9.38. In addition, Inovio Pharmaceuticals Inc. saw -6.89% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at INO starting from Shea Jacqueline Elizabeth, who sale 4,710 shares at the price of $8.97 back on Mar 26. After this action, Shea Jacqueline Elizabeth now owns 60,127 shares of Inovio Pharmaceuticals Inc., valued at $42,249 using the latest closing price.
BENITO SIMON X, the Director of Inovio Pharmaceuticals Inc., sale 2,000 shares at $10.41 during a trade that took place back on Mar 16, which means that BENITO SIMON X is holding 51,650 shares at $20,820 based on the most recent closing price.
Stock Fundamentals for INO
Current profitability levels for the company are sitting at:
- -1760.60 for the present operating margin
The net margin for Inovio Pharmaceuticals Inc. stands at -2245.39. The total capital return value is set at -43.13, while invested capital returns managed to touch -55.59. Equity return is now at value -57.60, with -37.80 for asset returns.
Based on Inovio Pharmaceuticals Inc. (INO), the company’s capital structure generated 8.47 points at debt to equity in total, while total debt to capital is 7.81. Total debt to assets is 7.18, with long-term debt to equity ratio resting at 7.96. Finally, the long-term debt to capital ratio is 7.34.
When we switch over and look at the enterprise to sales, we see a ratio of 134.97, with the company’s debt to enterprise value settled at 0.04. The receivables turnover for the company is 0.70 and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.30.